Please provide your email address to receive an email when new articles are posted on . Data from Australia’s annual bio-behavioral surveillance of people who inject drugs attending needle syringe ...

Please provide your email address to receive an email when new articles are posted on . Patients with hepatitis C have an increased risk for disease progression to cirrhosis and potentially ...

Direct-acting antiviral therapy has reduced the prevalence of hepatitis C viremia over time among adults with HIV infection in the United States. The prevalence of hepatitis C virus (HCV) has ...

Direct-acting antiviral (DAA) therapy for patients with chronic hepatitis C (CHC) is associated with a lower risk for liver and nonliver complications, as well as a "large and significant" 57% ...

obesity chronic disease illness The review analyzed 168 patients treated with an oral DAA at a single center from 2015 to 2017. In chronic hepatitis C (CHC) patients receiving direct-acting antiviral ...

Liver cirrhosis Curing HCV infection with direct-acting antiretrovirals is associated with regression of liver fibrosis for most patients. Curing hepatitis C virus (HCV) infection with direct-acting ...

Treatment of hepatitis C virus (HCV) with direct-acting antiviral medications was associated with low HCV reinfection rates among patients who inject drugs, although risk for reinfection was highest ...

In the decade since safe, curative oral treatments were approved for treating hepatitis C virus (HCV) infections, only 1 in 3 US patients diagnosed with the disease have been cleared of it, according ...

Investigators highlight the complications of a transmit-then-treat approach. Two weeks of direct-acting antiviral (DAA) prophylaxis may be optimal to prevent hepatitis C infection in recipients of ...

Objectives: To quantify the burden of illness of chronic hepatitis C virus (HCV) infection and estimate the impact of interferon-free direct-acting antiviral treatment on healthcare costs in Medicaid.